JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on December 20, 2005; DOI: 10.1124/jpet.105.093310


0022-3565/06/3163-1318-1327$20.00
JPET 316:1318-1327, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.093310v1
316/3/1318    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Birrell, M. A.
Right arrow Articles by Belvisi, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Birrell, M. A.
Right arrow Articles by Belvisi, M. G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DEXAMETHASONE

INFLAMMATION AND IMMUNOPHARMACOLOGY

Second-Generation Inhibitors Demonstrate the Involvement of p38 Mitogen-Activated Protein Kinase in Post-Transcriptional Modulation of Inflammatory Mediator Production in Human and Rodent Airways

Mark A. Birrell, Sissie Wong, Kerryn McCluskie, Matthew C. Catley, Elizabeth L. Hardaker, Saleem Haj-Yahia, and Maria G. Belvisi

Respiratory Pharmacology Group, Airway Diseases, Imperial College School of Medicine, National Heart and Lung Institute, Chelsea, London, United Kingdom (M.A.B., S.W., K.M., M.C.C., E.L.H., M.G.B.); and Royal Brompton and Harefield Hospital, London, United Kingdom (S.H.-Y.)

The exact role of p38 mitogen-activated protein kinase (MAPK) in the expression of inflammatory cytokines is not clear; it may regulate transcriptionally, post-transcriptionally, translationally, or post-translationally. The involvement of one or more of these mechanisms has been suggested to depend on the particular cytokine, the cell type studied, and the specific stimulus used. Interpretation of some of the published data is further complicated by the use of inhibitors such as 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB 203580) used at single, high concentrations. The aim of this study was to determine the impact of two second-generation p38 MAPK inhibitors on the expression of a range of inflammatory cytokines at the gene and protein levels in human cultured cells. Similar assessment of the impact of these compounds on inflammatory cytokine expression in a preclinical in vivo model of airway inflammation was performed. The results in THP-1 cells and primary airway macrophages clearly show that protein expression is inhibited at much lower concentrations of inhibitor than are needed to impact on gene expression. In the rodent model, both compounds, at doses that cause maximal inhibition of cellular recruitment, inhibit tumor necrosis factor {alpha} (TNF{alpha}) protein production without impacting on nuclear factor {kappa}B pathway activation or TNF{alpha} gene expression. In summary, the data shown here demonstrate that, although at high compound concentrations there is some level of transcriptional regulation, the predominant role of p38 MAPK in cytokine production is at the translational level. These data question whether the effect of p38 inhibitors on gene transcription is related to their potential therapeutic role as anti-inflammatory compounds.


Received July 27, 2005; accepted December 15, 2005.

Address correspondence to: Professor Maria G. Belvisi, Respiratory Pharmacology, Airway Diseases, Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK. E-mail: m.belvisi{at}imperial.ac.uk




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
L. M. Kent, L. J. C. Smyth, J. Plumb, C. L. Clayton, S. M. Fox, D. W. Ray, S. N. Farrow, and D. Singh
Inhibition of Lipopolysaccharide-Stimulated Chronic Obstructive Pulmonary Disease Macrophage Inflammatory Gene Expression by Dexamethasone and the p38 Mitogen-Activated Protein Kinase Inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504)
J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 458 - 468.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. A. Birrell, M. C. Catley, E. Hardaker, S. Wong, T. M. Willson, K. McCluskie, T. Leonard, S. N. Farrow, J. L. Collins, S. Haj-Yahia, et al.
Novel Role for the Liver X Nuclear Receptor in the Suppression of Lung Inflammatory Responses
J. Biol. Chem., November 2, 2007; 282(44): 31882 - 31890.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. J. Thorley, P. A. Ford, M. A. Giembycz, P. Goldstraw, A. Young, and T. D. Tetley
Differential Regulation of Cytokine Release and Leukocyte Migration by Lipopolysaccharide-Stimulated Primary Human Lung Alveolar Type II Epithelial Cells and Macrophages
J. Immunol., January 1, 2007; 178(1): 463 - 473.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.